PMID

Data

Article Title

Organization

Potent nonpeptide angiotensin II receptor antagonists. 2. 1-(Carboxybenzyl)imidazole-5-acrylic acids.

Smithkline Beecham Pharmaceuticals

Conformationally restricted polysubstituted biphenyl derivatives with angiotensin II receptors antagonist properties.

Searle R & D And Mcr

Nonpeptide angiotensin II receptor antagonists: the discovery of a series of N-(biphenylylmethyl)imidazoles as potent, orally active antihypertensives.

E. I. Du Pont De Nemours

Synthesis and structure-activity relationships of a novel series of non-peptide angiotensin II receptor binding inhibitors specific for the AT2 subtype.

Warner-Lambert

Nonpeptide angiotensin II receptor antagonists: N-[(benzyloxy)benzyl]imidazoles and related compounds as potent antihypertensives.

E. I. Du Pont De Nemours And

The discovery of potent nonpeptide angiotensin II receptor antagonists: a new class of potent antihypertensives.

E. I. Du Pont De Nemours

Topographic probes of angiotensin and receptor: potent angiotensin II agonist containing diphenylalanine and long-acting antagonists containing biphenylalanine and 2-indan amino acid in position 8.

Washington State University

 

2,3,6-Substituted quinazolinones as angiotensin II receptor antagonists

TBA

 

Synthesis and biological evaluation of the potent isoxazolidinyl angiotensin II receptor antagonist CL332,877 and its enantiomers.

TBA

 

6-isoxazolinyl and isoxazolidinyl substituted quinazolinones as angiotensin II receptor antagonists

TBA

4-(Heteroarylthio)-2-biphenylyltetrazoles as nonpeptide angiotensin II antagonists.

Burroughs Wellcome

Nonpeptide angiotensin II receptor antagonists. Synthesis, in vitro activity, and molecular modeling studies of N-[(heterobiaryl)methyl] imidazoles.

Istituto Lusofarmaco

Bromobenzofuran-based non-peptide antagonists of angiotensin II: GR138950, a potent antihypertensive agent with high oral bioavailability.

Glaxo Research And Development

Imidazole-5-acrylic acids: potent nonpeptide angiotensin II receptor antagonists designed using a novel peptide pharmacophore model.

Smithkline Beecham Pharmaceuticals